Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19: a case series

Xavier Solanich, Gardenia Vargas-Parra, Caspar I. van der Made, Annet Simons, Janneke Schuurs-Hoeijmakers, Arnau Antolí, Jesús del Valle, Gemma Rocamora-Blanch, Fernando Setién, Manel Esteller, Antoni Riera-Mestre, Joan Sabater-Riera, Gabriel Capellá, Frank L. van de Veerdonk, Ben van der Hoven, Xavier Corbella, Alexander Hoischen, Conxi Lázaro
doi: https://doi.org/10.1101/2021.03.14.21252289
Xavier Solanich
1Department of Medicina Interna. Hospital Universitari de Bellvitge - IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xsolanich{at}bellvitgehospital.cat Alexander.Hoischen{at}radboudumc.nl clazaro{at}iconcologia.net
Gardenia Vargas-Parra
2Hereditary Cancer Program, Catalan Institute of Oncology, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caspar I. van der Made
4Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
5Radboud University Medical Center Center for Infectious Diseases (RCI), Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
6Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
7Radboud Expertise Center for Immunodeficiency and Autoinflammation and Radboud Center for Infectious Disease (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annet Simons
4Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janneke Schuurs-Hoeijmakers
4Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnau Antolí
1Department of Medicina Interna. Hospital Universitari de Bellvitge - IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesús del Valle
2Hereditary Cancer Program, Catalan Institute of Oncology, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gemma Rocamora-Blanch
1Department of Medicina Interna. Hospital Universitari de Bellvitge - IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Setién
8Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manel Esteller
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
8Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain
9Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
10Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoni Riera-Mestre
1Department of Medicina Interna. Hospital Universitari de Bellvitge - IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain
11Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joan Sabater-Riera
12Department of intensive Care. Hospital Universitari de Bellvitge - IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel Capellá
2Hereditary Cancer Program, Catalan Institute of Oncology, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank L. van de Veerdonk
5Radboud University Medical Center Center for Infectious Diseases (RCI), Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
6Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
7Radboud Expertise Center for Immunodeficiency and Autoinflammation and Radboud Center for Infectious Disease (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben van der Hoven
13Department of Intensive Care, Erasmus MC, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Corbella
1Department of Medicina Interna. Hospital Universitari de Bellvitge - IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain
14School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Hoischen
4Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
5Radboud University Medical Center Center for Infectious Diseases (RCI), Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
6Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
7Radboud Expertise Center for Immunodeficiency and Autoinflammation and Radboud Center for Infectious Disease (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xsolanich{at}bellvitgehospital.cat Alexander.Hoischen{at}radboudumc.nl clazaro{at}iconcologia.net
Conxi Lázaro
2Hereditary Cancer Program, Catalan Institute of Oncology, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xsolanich{at}bellvitgehospital.cat Alexander.Hoischen{at}radboudumc.nl clazaro{at}iconcologia.net
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Advanced age, male sex and chronic comorbidities are associated with severe COVID-19. However, these general risk factors cannot explain why critical illness occurs in young and apparently healthy individuals. In the past months, several publications have identified susceptibility loci and genes using comprehensive GWAS studies or genome, exome or candidate genes analysis. A recent study reported rare, loss-of-function TLR7 variants in otherwise healthy young brother pairs from two families with severe COVID-19. We aimed to prospectively study the prevalence of rare X-chromosomal TLR7 genetic variants in our cohort of young male patients with severe COVID-19. We recruited 13 patients ≤50 years who had no risk factors known to be associated with severe disease. We studied the entire TLR7 coding region and identified two missense variants (p.Asn215Ser, c.644A>G and p.Trp933Arg, c.2797T>C) in two out of 13 cases (15.4%). These variants were not previously reported in population control databases (gnomAD) and were predicted to be damaging by all in silico predictors. The male index patients were between 25 and 30 years old and had no apparent comorbidities. The TLR7 p.Asn215Ser co-segregated in 2 first-degree relatives severely affected by COVID-19, in a younger previously healthy the variant was found in hemizygous state, and in an older than 60 was in heterozygous state. No family members were available for testing the segregation of the p.Trp933Arg variant. These results further support that susceptibility to severe COVID-19 could be determined by inherited rare genetic variants in TLR7. Understanding the causes and mechanisms of life-threatening COVID-19 is crucial and could lead to novel preventive and therapeutic options. This study supports a rationale for the genetic screening for TLR7 variants in young men with severe COVID-19 in the absence of other relevant risk factors. A diagnosis of TLR7 deficiency could not only inform on treatment options for the patient, but it also enables for pre-symptomatic testing of at-risk male relatives with the possibility of instituting early preventive and therapeutic interventions.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Contract grant sponsor: Supported by the Carlos III National Health Institute funded by FEDER funds; a way to build Europe [PI19/00553 and CIBERONC]; 2017SGR1282 and 2017SGR496]. AH is supported by the SolveRD project. The SolveRD project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No. 779257. FvdV was supported by a ZonMW (The Netherlands Organization for Health Research and Development) Vidi grant (No. 91718351). This research was part of the Netherlands Xomics Initiative and partially funded by NWO (The Netherlands Organization for Scientific Research; project 184.034.019)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Informed consent was obtained from all patients and relatives included in the study. The IDIBELL Research Ethics Committee approved this study (PR152/20).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19: a case series
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19: a case series
Xavier Solanich, Gardenia Vargas-Parra, Caspar I. van der Made, Annet Simons, Janneke Schuurs-Hoeijmakers, Arnau Antolí, Jesús del Valle, Gemma Rocamora-Blanch, Fernando Setién, Manel Esteller, Antoni Riera-Mestre, Joan Sabater-Riera, Gabriel Capellá, Frank L. van de Veerdonk, Ben van der Hoven, Xavier Corbella, Alexander Hoischen, Conxi Lázaro
medRxiv 2021.03.14.21252289; doi: https://doi.org/10.1101/2021.03.14.21252289
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19: a case series
Xavier Solanich, Gardenia Vargas-Parra, Caspar I. van der Made, Annet Simons, Janneke Schuurs-Hoeijmakers, Arnau Antolí, Jesús del Valle, Gemma Rocamora-Blanch, Fernando Setién, Manel Esteller, Antoni Riera-Mestre, Joan Sabater-Riera, Gabriel Capellá, Frank L. van de Veerdonk, Ben van der Hoven, Xavier Corbella, Alexander Hoischen, Conxi Lázaro
medRxiv 2021.03.14.21252289; doi: https://doi.org/10.1101/2021.03.14.21252289

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)